Spina bifida in infants of women treated with carbamazepine during pregnancy

New England Journal of Medicine

Volumn 324, Issue 10, 1991, Pages 674-677

  Rosa, Franz W ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

ADVERSE DRUG REACTION; ARTICLE; DRUG TOXICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; PRIORITY JOURNAL; SEIZURE; SPINA BIFIDA;

EID: 0026030573     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199103073241006     Document Type: Article

References (26)

1. Robert E., Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982; 2:937.
2. Rosa F. Pregnancy outcomes with maternal carbamazepine exposure. Food and Drug Administration ADR highlights. Rock ville, Md.: Food and Drug Administration, 1983. (Document no. 1983-ADR No. 11.)
3. Lindhout D., Meinardi H. Spina bifida and in-utero exposure to valproate. Lancet 1984: 2:396.
4. Jones K.L., Lacro R.V., Johnson K.A., Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320:1661-1666
5. Jones K.L., Johnson K.A., Adams J., Lacro R.V. Teratogenic effects of carbamazepine. N Engl J Med 1989; 321:1481.
6. Lindhout D. Confirmation of valproic acid as a human teratogen. Presented at the Teratology Society Meeting, Richmond Va. June 7, 1989. abstract.
7. Nakane Y., Okuma T., Takahashi R., et al. Multi-institutional study on teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980; 21:663-680
8. French Chapter of International League Against Epilepsy. Teratogenic risk of antiepileptic drugs with special reference to sodium valproate. In: Porter RJ, ed. Advances in epileptology. New York: Raven Press, 1984: 299-307.
9. Kaneko S., Otani K., Fukushima Y., et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988; 29:459-467
10. Johnson K.C., Helston D.R., Sherman G.J. Anticonvulsant use and congenital malformations in Saskatchewan: creation of a prescription drug use-pregnancy outcome database. J Clin Res Drug Dev 1989; 3:215.
11. De Giambattista M., Como M.L., Fumarola C., et al. Malformations in offspring of 319 pregnant women in treatment with antiepileptic drugs. Presented at the Third International Conference of Teratogen Information Services, Park City, Utah, February 26–28, 1990. abstract.
12. Starre ve Id-Zimmerman A.A., Van der Kolk W.J., Meinardi H., Elshove J. Are anticonvulsants teratogenic? Lancet 1973; 2:48-49
13. Kallen B. A registry study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurol Scand 1986; 73:253-259
14. Bertollini R., Kallen B., Mastroiacovo P., Robert E. Anticonvulsant drugs in monotherapy: effect on the fetus. Eur J Epidemiol 1987; 3:164-171
15. Holmes L.P., Harvey E.A., Hayes A.M., et al. The teratogenic effects of anticonvulsant monotherapy: phenobarbital, carbamazepine, and phenytoin. Teratology 1990; 41:565. abstract.
16. Hiilesmaa V., Teramo K., Granstrom M.L., Bardy A.H. Fetal head growth retardation associated with maternal antiepileptic drugs. Lancet 1981; 2:165-167
17. Gladstone D.J., Bologa M., Maguire, Koren G. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Presented at the Third International Conference of Teratogen Information Services, Park City, Utah, February 26–28, 1990. abstract.
18. Robert E., Lofkvist E., Mauguiere F., Robert J.M. Evaluation of drug therapy and teratogenic risk in Rhone-Alpes district population of pregnant epileptic women. Eur Neurol 1986; 25:436-443
19. Meyer J.G. The teratological effects of anticonvulsants and the effects on pregnancy and birth. Eur Neurol 1973; 10:179-190
20. Barry J.E., Danks D.M. Anticonvulsants and congenital abnormalities. Lancet 1974; 2:48-49
21. Kuhnz W., Jager-Roman E., Rating D., et al. Carbamazepine and carbamazepine-10,11-epoxide during pregnancy and postnatal period in epileptic mothers and their nursed infants: pharmacokinetics and clinical effects. Pediatr Pharmacol 1983; 3:199-208.
22. Chitayat D., McGillivray B., Bamforth S., Hall J.G. Prospective study and follow up of women with valproate (VPA) exposure during pregnancy. Teratology 1987; 35:69A. abstract.
23. Kelly T.E., Edwards S.P., Rein M., Miller J.Q., Dreifuss F.E. Teratogenicity of anticonvulsant drugs. II. A prospective study. Am J Med Genet 1984; 19:423-443
24. Fedrick J. Epilepsy and pregnancy: a report of the Oxford Record Linkage Study. BMJ 1973; 2:442-448
25. Millar J.H.D., Nevin N.C. Congenital malformations and anticonvulsant drugs. Lancet 1973; 1:328.
26. International Clearinghouse for Birth Defects Monitoring Systems. In: Knudsen L, ed. Annual report 1985. Copenhagen, Denmark: National Board of Health, 1985: 17.